GB9311281D0
(en)
*
|
1993-06-01 |
1993-07-21 |
Rhone Poulenc Rorer Ltd |
Novel composition of matter
|
US5698711A
(en)
*
|
1991-01-28 |
1997-12-16 |
Rhone-Poulenc Rorer Limited |
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
|
US6096768A
(en)
*
|
1992-01-28 |
2000-08-01 |
Rhone-Poulenc Rorer Limited |
Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
|
AU6526896A
(en)
*
|
1995-07-22 |
1997-02-18 |
Rhone-Poulenc Rorer Limited |
Substituted aromatic compounds and their pharmaceutical use
|
US6211203B1
(en)
*
|
1996-08-19 |
2001-04-03 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Benzofuran-4-carboxamides
|
US5874437A
(en)
*
|
1996-11-01 |
1999-02-23 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
US5958926A
(en)
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
AU722480B2
(en)
*
|
1996-11-01 |
2000-08-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
USRE37234E1
(en)
*
|
1996-11-01 |
2001-06-19 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
|
IL130658A
(en)
*
|
1997-02-17 |
2004-07-25 |
Altana Pharma Ag |
Preparations for the treatment of ARDS or IRDS containing 3 - (cyclopropylmethoxy) - N - (3, 5 - dichloro - 4 - pyridinyl) - 4 - (difluoromethoxy) benzamide and solvent for the lungs
|
US6472425B1
(en)
|
1997-10-31 |
2002-10-29 |
Nitromed, Inc. |
Methods for treating female sexual dysfunctions
|
US6172118B1
(en)
*
|
1998-04-14 |
2001-01-09 |
Smithkline Beecham Corporation |
Compounds
|
AU3284000A
(en)
|
1999-03-10 |
2000-09-28 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis
|
US6653309B1
(en)
*
|
1999-04-26 |
2003-11-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of IMPDH enzyme technical field of the invention
|
SI1176960T1
(en)
*
|
1999-05-04 |
2005-04-30 |
Altana Pharma Ag |
Synergistic combination comprising roflumilast and a pde-3 inhibitor
|
SI1212089T1
(sl)
*
|
1999-08-21 |
2006-08-31 |
Altana Pharma Ag |
Sinergisticna kombinacija roflumilasta in salmeterola
|
CA2407780A1
(en)
|
2000-05-25 |
2001-11-29 |
Merck Frosst Canada & Co./Merck Frosst Canada & Cie |
Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
|
DE10043074A1
(de)
|
2000-09-01 |
2002-03-14 |
Aventis Cropscience Gmbh |
Herbizid wirksame Benzoylcyclohexandione
|
EP1199074A1
(en)
*
|
2000-09-15 |
2002-04-24 |
Warner-Lambert Company |
Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
|
EP1188438A1
(en)
*
|
2000-09-15 |
2002-03-20 |
Warner-Lambert Company |
Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
|
AU2002227123A1
(en)
*
|
2000-11-07 |
2002-05-21 |
Merck And Co., Inc. |
Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
|
US20100310477A1
(en)
*
|
2000-11-28 |
2010-12-09 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg. |
Pharmaceutical compositions based on anticholingerics and additional active ingredients
|
US6699890B2
(en)
|
2000-12-22 |
2004-03-02 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US7205320B2
(en)
*
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
US6872382B1
(en)
|
2001-05-21 |
2005-03-29 |
Alcon, Inc. |
Use of selective PDE IV inhibitors to treat dry eye disorders
|
EP1397359B1
(en)
|
2001-05-24 |
2005-08-31 |
Merck Frosst Canada & Co. |
1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
|
NZ531153A
(en)
*
|
2001-08-09 |
2005-10-28 |
Ono Pharmaceutical Co |
Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
|
DE10207160A1
(de)
*
|
2002-02-20 |
2003-12-18 |
Altana Pharma Ag |
Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff
|
MY140561A
(en)
|
2002-02-20 |
2009-12-31 |
Nycomed Gmbh |
Dosage form containing pde 4 inhibitor as active ingredient
|
TWI347845B
(en)
*
|
2002-03-06 |
2011-09-01 |
Nycomed Gmbh |
Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
|
EP1517706A2
(en)
*
|
2002-05-07 |
2005-03-30 |
ALTANA Pharma AG |
Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
|
US20050222193A1
(en)
*
|
2002-05-07 |
2005-10-06 |
Guido Hanauer |
Novel combination for the treatment of airway disorders
|
WO2003097050A2
(en)
*
|
2002-05-16 |
2003-11-27 |
Pharmacia Corporation |
A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
|
DE60325354D1
(de)
*
|
2002-05-28 |
2009-01-29 |
Nycomed Gmbh |
Topisch anwendbare pharmazeutische zubereitung
|
AU2003256601B2
(en)
|
2002-07-19 |
2009-10-29 |
Memory Pharmaceuticals Corporation |
6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
|
EP1539697A1
(en)
|
2002-07-19 |
2005-06-15 |
Memory Pharmaceutical Corporation |
Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
|
WO2004022536A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Glenmark Pharmaceuticals Limited |
New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
|
WO2004021987A2
(en)
*
|
2002-09-06 |
2004-03-18 |
Merck & Co., Inc. |
Treatment of rheumatoid arthritis by inhibition of pde4
|
EP1542768A1
(en)
*
|
2002-09-20 |
2005-06-22 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
US6822114B1
(en)
|
2002-10-08 |
2004-11-23 |
Albemarle Corporation |
Process for production of fluoroalkoxy-substituted benzamides and their intermediates
|
EA010408B1
(ru)
|
2002-10-23 |
2008-08-29 |
Гленмарк Фармасьютикалс Лтд. |
Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
|
EP1569908B1
(en)
*
|
2002-11-19 |
2010-09-15 |
Memory Pharmaceuticals Corporation |
Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
|
US20060142308A1
(en)
*
|
2002-11-27 |
2006-06-29 |
Atlanta Pharma Ag |
Synergistic combination comprising roflumilast and formoterol
|
US20060083714A1
(en)
*
|
2003-01-27 |
2006-04-20 |
Warner James M |
Combination of a pde iv inhibitor and a tnf-alpha antagonist
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
ES2335498T3
(es)
|
2003-03-10 |
2010-03-29 |
Nycomed Gmbh |
Nuevo proceso para la preparacion de reflumilast.
|
EP1624893A2
(en)
|
2003-04-01 |
2006-02-15 |
Applied Research Systems ARS Holding N.V. |
Inhibitors of phosphodiesterases in infertility
|
KR20060017494A
(ko)
|
2003-04-11 |
2006-02-23 |
그렌마크 파머수티칼스 에스. 아. |
염증 및 알레르기성 질환 치료용으로 유용한 신규 헤테로사이클릭 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물
|
DE10318610A1
(de)
*
|
2003-04-24 |
2004-11-11 |
Elbion Ag |
7-Azaindole und deren Verwendung als Therapeutika
|
WO2004098595A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
|
WO2004098596A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising roflumilast and il-1 trap
|
WO2004098598A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
|
WO2004098597A1
(en)
*
|
2003-05-12 |
2004-11-18 |
Altana Pharma Ag |
Composition comprising roflumilast and shuil-1r ii
|
JP2006528229A
(ja)
|
2003-05-22 |
2006-12-14 |
アルタナ ファルマ アクチエンゲゼルシャフト |
Pde4阻害剤及びpde5阻害剤を含有する組成物
|
RS20050890A
(en)
*
|
2003-05-30 |
2007-12-31 |
Ranbaxy Laboratories Limited, |
Substituted pyrrole derivatives
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US7825147B2
(en)
*
|
2003-08-29 |
2010-11-02 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-IV
|
US7776893B2
(en)
*
|
2003-09-05 |
2010-08-17 |
Nycomed Gmbh |
Use of PDE4 inhibitors for the treatment of diabetes mellitus
|
EP1670742A1
(en)
*
|
2003-09-12 |
2006-06-21 |
Ranbaxy Laboratories Limited |
Process for the preparation of roflumilast
|
WO2005046676A1
(en)
*
|
2003-11-12 |
2005-05-26 |
University Of South Carolina |
Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic amp-specific phosphodiesterase inhibitors
|
PT1685849E
(pt)
*
|
2003-11-20 |
2012-02-15 |
Astellas Pharma Inc |
Inibidores de pde4 para o tratamento da cistite intersticial
|
WO2005051931A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
MY141255A
(en)
*
|
2003-12-11 |
2010-03-31 |
Memory Pharm Corp |
Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
|
PL1713473T3
(pl)
*
|
2004-02-06 |
2013-08-30 |
Meda Pharma Gmbh & Co Kg |
Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
|
ATE541570T1
(de)
*
|
2004-02-06 |
2012-02-15 |
Meda Pharma Gmbh & Co Kg |
Kombination von anticholinergika und hemmern von phosphodiesterase typ 4 zur behandlung von atemwegserkrankungen
|
CA2556086C
(en)
|
2004-02-18 |
2014-04-01 |
Altana Pharma Ag |
Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
|
EP1720543A1
(en)
*
|
2004-02-27 |
2006-11-15 |
Altana Pharma AG |
Roflumilast and glycopryrronium combination
|
ES2505473T3
(es)
|
2004-03-03 |
2014-10-10 |
Takeda Gmbh |
Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la PDE4
|
US20060035939A1
(en)
*
|
2004-07-14 |
2006-02-16 |
Japan Tobacco Inc. |
3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
|
EP1777225A4
(en)
|
2004-07-15 |
2009-06-24 |
Japan Tobacco Inc |
FUSED BENZAMIDE COMPOUND AND INHIBITOR OF VANILLOID RECEPTOR 1 (VR1) ACTIVITY
|
US20080009535A1
(en)
*
|
2004-08-30 |
2008-01-10 |
Sarala Balachandran |
Inhibitors of phosphodiesterase type-IV
|
DE102004046236A1
(de)
*
|
2004-09-22 |
2006-03-30 |
Altana Pharma Ag |
Arzneimittelzubereitung
|
DE102004046235A1
(de)
|
2004-09-22 |
2006-03-30 |
Altana Pharma Ag |
Arzneimittelzubereitung
|
EP1813284A1
(en)
*
|
2004-10-13 |
2007-08-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Pharmaceutical composition
|
EP1810692A1
(en)
*
|
2004-10-13 |
2007-07-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Remedies/preventives for chronic skin disease
|
JP2009519206A
(ja)
|
2004-10-13 |
2009-05-14 |
グレンマーク・ファーマシューティカルズ・エスエー |
N−(3,5−ジクロロピリジン−4−イル)−4−ジフルオロメトキシ−8−メタンスルホンアミド−ジベンゾ[b,d]フラン−1−カルボキサミドの製造法
|
PL1831227T3
(pl)
|
2004-12-17 |
2013-10-31 |
Glenmark Pharmaceuticals Sa |
Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
|
SI1831227T1
(sl)
|
2004-12-17 |
2013-09-30 |
Glenmark Pharmaceuticals S.A. |
Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
|
WO2006094640A2
(en)
*
|
2005-03-04 |
2006-09-14 |
F.Hoffmann-La Roche Ag |
Roflumilast and integrin inhibitor combination and method of treatment
|
WO2006094942A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Nycomed Gmbh |
Roflumilast for the treatment of diabetes mellitus
|
BRPI0609371A2
(pt)
*
|
2005-03-08 |
2010-03-30 |
Nycomed Gmbh |
usos de roflumilast na produção de composições farmacêuticas para o tratamento de diabetes mellitus
|
EP1863476B1
(en)
*
|
2005-03-16 |
2016-02-03 |
MEDA Pharma GmbH & Co. KG |
The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
|
CA2601250C
(en)
|
2005-03-16 |
2014-10-28 |
Nycomed Gmbh |
Taste masked dosage form containing roflumilast
|
KR101358479B1
(ko)
|
2005-04-19 |
2014-02-06 |
다케다 게엠베하 |
폐고혈압 치료용 로플루밀라스트
|
BRPI0612796A2
(pt)
*
|
2005-05-11 |
2010-11-30 |
Nycomed Gmbh |
combinação de um inibidor da pde4 e um derivado da tetraidrobiopterina
|
RU2007149249A
(ru)
*
|
2005-06-09 |
2009-07-20 |
Сантен Фармасьютикал Ко., Лтд (Jp) |
Глазные капли, содержащие рофлумиласт
|
CA2620333A1
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
WO2007053596A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
AU2006313430B2
(en)
*
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
PL2098248T3
(pl)
|
2005-12-21 |
2012-11-30 |
Meda Pharma Gmbh & Co Kg |
Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
|
US7906508B2
(en)
|
2005-12-28 |
2011-03-15 |
Japan Tobacco Inc. |
3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
|
US7863446B2
(en)
*
|
2006-01-19 |
2011-01-04 |
Orchid Research Laboratories Limited |
Heterocycles
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
CA2643199A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20070238716A1
(en)
*
|
2006-03-14 |
2007-10-11 |
Murthy Ayanampudi S R |
Statin stabilizing dosage formulations
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
ME01648B
(me)
|
2006-07-05 |
2014-09-20 |
Nycomed Gmbh |
Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja
|
JP2009543773A
(ja)
*
|
2006-07-14 |
2009-12-10 |
ランバクシー ラボラトリーズ リミテッド |
HMG−CoAレダクターゼ阻害剤の多形体及びその使用
|
WO2008026687A1
(fr)
|
2006-09-01 |
2008-03-06 |
Kyorin Pharmaceutical Co., Ltd. |
Dérivé de pyrazolopyridine carboxamide et inhibiteur de phosphodiestérase (pde) comprenant le dérivé
|
AU2007292848A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20080103165A1
(en)
*
|
2006-09-19 |
2008-05-01 |
Braincells, Inc. |
Ppar mediated modulation of neurogenesis
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2066661A2
(en)
*
|
2006-09-22 |
2009-06-10 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
US20080221103A1
(en)
*
|
2007-03-09 |
2008-09-11 |
Orchid Research Laboratories Ltd. |
New heterocyclic compounds
|
KR100844125B1
(ko)
*
|
2007-03-23 |
2008-07-04 |
한국화학연구원 |
7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-a]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
|
WO2008138939A1
(en)
|
2007-05-16 |
2008-11-20 |
Nycomed Gmbh |
Pyrazolone derivatives as pde4 inhibitors
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
WO2009088054A1
(ja)
|
2008-01-11 |
2009-07-16 |
Astellas Pharma Inc. |
精巣の疼痛又は不快感行動及び頻尿併発モデル動物
|
EP2245017A4
(en)
|
2008-02-01 |
2011-12-28 |
Orchid Res Lab Ltd |
NEW HETEROCYCLES
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
WO2010003084A2
(en)
*
|
2008-07-02 |
2010-01-07 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2216327A1
(en)
|
2009-02-06 |
2010-08-11 |
CHIESI FARMACEUTICI S.p.A. |
Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
WO2011143106A1
(en)
|
2010-05-10 |
2011-11-17 |
Gilead Sciences, Inc. |
Bi - functional pyrazolopyridine compounds
|
UY33372A
(es)
|
2010-05-10 |
2011-12-30 |
Gilead Sciences Inc |
?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
|
NZ603895A
(en)
*
|
2010-06-24 |
2014-10-31 |
Leo Pharma As |
Novel phosphodiesterase inhibitors
|
CN102311382B
(zh)
*
|
2010-06-29 |
2014-05-21 |
大道隆达(北京)医药科技发展有限公司 |
罗氟司特的晶态及其制备方法
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
CN102093194B
(zh)
*
|
2010-12-24 |
2014-01-08 |
江苏先声药物研究有限公司 |
3-环丙基甲氧基-4-二氟甲氧基苯甲酸的合成方法
|
CN102617457A
(zh)
*
|
2011-01-28 |
2012-08-01 |
天津药物研究院 |
一种制备罗氟司特的新方法
|
EP3366698A1
(en)
|
2011-03-01 |
2018-08-29 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase c agonists
|
CN102690194B
(zh)
*
|
2011-03-24 |
2014-06-25 |
上海通远生物科技有限公司 |
3-环丙基甲氧基-4-二氟甲氧基苯甲酸的制备方法
|
CN102775345A
(zh)
*
|
2011-05-13 |
2012-11-14 |
上海特化医药科技有限公司 |
制备罗氟司特的方法及中间体
|
CN102276522B
(zh)
*
|
2011-06-15 |
2013-04-17 |
无锡泓兴生物医药科技有限公司 |
一种制备罗氟司特的方法及其中间体
|
CN102336703B
(zh)
*
|
2011-07-20 |
2013-09-25 |
华润赛科药业有限责任公司 |
一种制备罗氟司特的方法
|
CN102351787B
(zh)
*
|
2011-08-18 |
2014-08-13 |
天津市汉康医药生物技术有限公司 |
高生物利用度的罗氟司特化合物
|
WO2013030789A1
(en)
|
2011-08-30 |
2013-03-07 |
Ranbaxy Laboratories Limited |
Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
|
CN102336704B
(zh)
*
|
2011-10-19 |
2013-04-17 |
丁克 |
一种制备罗氟司特的方法
|
RU2617401C2
(ru)
*
|
2011-10-21 |
2017-04-25 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстеразы
|
CN102336705B
(zh)
*
|
2011-10-28 |
2013-03-27 |
成都苑东药业有限公司 |
一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
|
CN104080770A
(zh)
*
|
2011-11-09 |
2014-10-01 |
迈兰实验室有限公司 |
用于制备罗氟司特的改进方法
|
WO2013081565A1
(en)
|
2011-11-21 |
2013-06-06 |
Mahmut Bilgic |
Pharmaceutical compositions comprising roflumilast and terbutaline
|
WO2013077830A1
(en)
|
2011-11-25 |
2013-05-30 |
Mahmut Bilgic |
Synergistilly active combinations of roflumilast and carmoterol
|
WO2013084182A1
(en)
|
2011-12-08 |
2013-06-13 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
|
CN102603623A
(zh)
*
|
2011-12-26 |
2012-07-25 |
北京赛林泰医药技术有限公司 |
制备高纯度罗氟司特的方法
|
US20150119399A1
(en)
|
2012-01-10 |
2015-04-30 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
WO2013131255A1
(en)
|
2012-03-07 |
2013-09-12 |
Scinopharm (Changshu) Pharmaceutical, Ltd. |
Preparation method of roflumilast
|
WO2014012954A1
(en)
|
2012-07-18 |
2014-01-23 |
Takeda Gmbh |
Treatment of partly controlled or uncontrolled severe asthma
|
CN103630613B
(zh)
*
|
2012-08-21 |
2015-08-05 |
北大方正集团有限公司 |
分离并检测罗氟司特及其中间体的方法
|
US9321726B2
(en)
|
2012-10-17 |
2016-04-26 |
Interquim, S.A. |
Process for preparing roflumilast
|
PL2948148T3
(pl)
*
|
2013-01-28 |
2021-01-25 |
Incozen Therapeutics Pvt. Ltd. |
Sposoby leczenia zaburzeń autoimmunologicznych, oddechowych i zapalnych przez wziewne podawanie n-tlenku roflumilastu
|
CA2899963A1
(en)
|
2013-02-04 |
2014-08-07 |
Grunenthal Gmbh |
Novel substituted condensed pyrimidine compounds
|
AU2014211755B2
(en)
|
2013-02-04 |
2017-07-06 |
Grunenthal Gmbh |
4-amino substituted condensed pyrimidine compounds as PDE4 inhibitors
|
JP6499591B2
(ja)
|
2013-02-25 |
2019-04-10 |
シナジー ファーマシューティカルズ インコーポレイテッド |
結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
TW201512189A
(zh)
|
2013-04-16 |
2015-04-01 |
Gruenenthal Chemie |
新型被取代之嘧啶縮合化合物
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
CN103304475A
(zh)
*
|
2013-06-13 |
2013-09-18 |
湖南千金湘江药业股份有限公司 |
苯甲酰胺化合物及其制备方法和用途
|
ES2644367T3
(es)
|
2013-08-09 |
2017-11-28 |
Grünenthal GmbH |
Nuevos compuestos de pirimidina condensados sustituidos
|
EP3492106B1
(en)
|
2013-08-09 |
2021-02-17 |
Ardelyx, Inc. |
Compounds and methods for inhibiting phosphate transport
|
DK3033082T3
(da)
|
2013-08-16 |
2021-09-20 |
Univ Maastricht |
Behandling af kognitiv svækkelse med pde4-hæmmer
|
WO2015063669A1
(en)
|
2013-10-30 |
2015-05-07 |
Wockhardt Limited |
Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
|
EA201692111A1
(ru)
|
2014-05-12 |
2017-08-31 |
Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед |
Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
|
AR101198A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Pirimidinas 2,5-sustituidas como inhibidores de pde4b
|
AR101197A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Pirimidinas 2,5-sustituidas
|
AR101196A1
(es)
|
2014-07-16 |
2016-11-30 |
Gruenenthal Gmbh |
Compuestos de pirimidina sustituidos
|
CN104130116B
(zh)
*
|
2014-08-18 |
2015-11-11 |
朱丽平 |
一种制备罗氟司特中间体的方法
|
WO2016063906A1
(ja)
|
2014-10-24 |
2016-04-28 |
久光製薬株式会社 |
プロドラッグ
|
CN104447245B
(zh)
*
|
2014-10-29 |
2017-06-06 |
成都森科制药有限公司 |
罗氟司特中间体、中间体制备方法及罗氟司特的制备方法
|
KR20170034707A
(ko)
|
2015-09-21 |
2017-03-29 |
한미약품 주식회사 |
로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
|
EP3165224A1
(en)
|
2015-11-09 |
2017-05-10 |
Albert-Ludwigs-Universität Freiburg |
Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
|
WO2017089347A1
(en)
|
2015-11-25 |
2017-06-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
|
CN105523954B
(zh)
*
|
2016-02-05 |
2017-07-18 |
徐江平 |
3‑环丙甲氧基‑4‑烷氧基苯甲酰胺类磷酸二酯酶4抑制剂
|
US20200155524A1
(en)
|
2018-11-16 |
2020-05-21 |
Arcutis, Inc. |
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
|
US11129818B2
(en)
|
2017-06-07 |
2021-09-28 |
Arcutis Biotherapeutics, Inc. |
Topical roflumilast formulation having improved delivery and plasma half life
|
US12011437B1
(en)
|
2017-06-07 |
2024-06-18 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
US9895359B1
(en)
|
2017-06-07 |
2018-02-20 |
Arcutis, Inc. |
Inhibition of crystal growth of roflumilast
|
US20210161870A1
(en)
|
2017-06-07 |
2021-06-03 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
US11534493B2
(en)
|
2017-09-22 |
2022-12-27 |
Arcutis Biotherapeutics, Inc. |
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
|
EP3700529A1
(en)
|
2017-10-23 |
2020-09-02 |
Boehringer Ingelheim International GmbH |
New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
|
JP7492918B2
(ja)
|
2018-06-04 |
2024-05-30 |
アーキュティス・バイオセラピューティクス・インコーポレーテッド |
ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
|
JP2022533251A
(ja)
|
2019-05-21 |
2022-07-21 |
アルデリックス, インコーポレイテッド |
患者において血清リン酸塩を低下させるための組み合わせ
|
MX2022009399A
(es)
|
2020-01-31 |
2022-09-19 |
Arcutis Biotherapeutics Inc |
Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica.
|
WO2021213455A1
(zh)
|
2020-04-23 |
2021-10-28 |
浙江养生堂天然药物研究所有限公司 |
药物组合及其用途
|
CN111777550A
(zh)
*
|
2020-06-01 |
2020-10-16 |
山东希尔康泰药业有限公司 |
罗氟司特结晶性粉末原料药生产制备方法
|
IL303379A
(en)
|
2020-12-04 |
2023-08-01 |
Arcutis Biotherapeutics Inc |
A topical formulation of ROFLUMILAST with antifungal activity
|
EP4282413A1
(en)
*
|
2021-01-21 |
2023-11-29 |
Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. |
Composition and method for treating tumors
|
WO2022169615A1
(en)
|
2021-02-05 |
2022-08-11 |
Arcutis Biotherapeutics, Inc. |
Roflumilast formulations with an improved pharmacokinetic profile
|
WO2023129892A1
(en)
|
2021-12-28 |
2023-07-06 |
Arcutis Biotherapeutics, Inc. |
Topical aerosol foams
|
WO2023129215A1
(en)
|
2021-12-28 |
2023-07-06 |
Arcutis Biotherapeutics, Inc. |
Topical roflumilast aerosol foams
|
US20240108609A1
(en)
|
2022-09-15 |
2024-04-04 |
Arcutis Biotherapeutics, Inc. |
Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug
|